Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan/Amlodipine FDC vs Free Combination in Hypertension
NCT06487949Phase 4Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valsartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Mean 24 hours systolic blood pressure at 8 weeks, Mean 24 hours diastolic blood pressure at 8 weeks and 1 more. Started Dec 2022; status: completed.
02
Drugs
valsartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06487949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487949.